Phase 2 N=20 A Study Using The Experimental Drug Called Imatinib (Gleevec) in Subjects With Systemic Sclerosis
Alveolitis · Systemic Sclerosis
Primary: Treatment-related Adverse Events — 5 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=206 Antifugal Effect of Recombinant Human Granulocyte-macrophage Stimulating Factor (rhGM-CSF) in Patients Post Allo-HSCT
Mycoses
Primary: Incidences of Invasive Fungal Diseases (IFD) — 11.76; 10.14; 23.19 percentage of partipants
Phase 3 N=720 PF-00299804 in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Not Responding to Standard Therapy for Advanced or Metastatic Cancer
Lung Cancer
Primary: Overall Survival — 6.83; 6.31 Months — p=0.506
N/A N=370 Model 4968 CAPTURE EPI® STERIOD-ELUTING BIPOLAR EPICARDIAL PACING LEAD Post-approval Study
Arrhythmia · Heart Failure
Primary: Survival Probability of the Model 4968 Lead Based on Lead-related Complications — 92.3 percentage of Model 4968 Leads
N/A N=10 Pilot Study Using a Wireless Motility Capsule
Food Selection
Primary: Whole Gut Transit Time — 22.5; 31.4 hours
Phase 2 N=26 Everolimus Plus Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma
Diffuse Large B-cell Lymphoma
Primary: Overall Response Rate — 38 percentage of participants
Phase 4 N=78 The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel
Hypogonadism
Primary: Percentage of Participants Achieving Normal Serum Testosterone Levels — 94.7 percentage of participants
N/A N=49 Optimal Planning Target Volume With Stereotactic Radiosurgery
Brain Neoplasms · Brain Cancer
Primary: 12-month Local Control Rate — 91.4; 95.2 percentage of lesions
Phase 1 N=12 Bioequivalence of Orfadin 20 mg Compared to Orfadin 10 mg Capsules.
Healthy
Primary: The Area Under the Serum Concentration vs. Time Profile During 72 Hours After Dose (AUC72h). — 262; 267 uM*h
Phase 4 N=440 Research Evaluating a PDE5 Inhibitor for Erectile Dysfunction
Erectile Dysfunction
Primary: Per-subject Proportion of Sexual Attempts That Had an Erectogenic Effect Within Approximately 15 Minutes Following Dosing — 14.9; 25.9; 29.1 percentage of successes
Phase 3 N=93 Comparison of the Efficacy and Safety of T2750 and Vismed® in the Treatment of Moderate to Severe Dry Eye Syndrome
Dry Eye Syndromes
Primary: Global Ocular Staining (With Oxford Scale - Ranges :0-15) — -1.8; -2 scores on a scale
Phase 3 N=546 Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma.
Carcinoma
Primary: Overall Survival (OS) — 7.56; 7.33 Months
Phase 2 N=30 Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Multiple Oral Bedtime Doses of ORMD-0801 in Adult Patients With Type 2 Diabetes Mellitus (T2DM)
Diabetes Mellitus Type 2
Primary: Evaluate the Safety and Tolerability of ORMD-0801. — 0; 0; 0 Number of Events
Phase 3 N=35 Memantine Plus Es-citalopram in Elderly Depressed Patients With Cognitive Impairment
Mild Cognitive Impairment · Major Depressive Disorder · Alzheimer's Disease
Primary: Change in Selective Reminding Test - Total Immediate Recall (SRT-IR) — 7.5 units on a scale
N/A N=16 Comparison of Carotenoid Bioavailability From Fresh Papaya, Tomato and Carrot
Focus of Study: Carotenoid Absorption
Primary: Pharmacokinetics of Carotenoid Absorption From Papaya, Carrot and Tomato — 163; 62; 64; 174 nmol*h/L